Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics adds to leadership team

Dr Dmitry Samarsky and Dr Andy Richards join

London-headquartered RNA therapeutics specialist Silence Therapeutics has appointed Dr Dmitry Samarsky as its new chief scientific officer, to take effect on 14 September.

Dr Samarsky joins the company from OliX Pharmaceuticals, where he served as senior vice president of technology and global business development.

Prior to this, he held the same title at RiboBio, an oligonucleotide-focused biotech based in China, between 2011 and 2015, and served as vice president of technology development at RXi Pharmaceuticals and director of technology development at Dharmacon.

Ali Mortazavi, chief executive officer of Silence Therapeutics, said: “We have undertaken an extensive search to find a CSO with experience in RNA therapeutics and are pleased to have recruited Dmitry, who brings a combination of deep technical expertise and commercial knowledge to Silence.

“Dmitry will be key in leading our efforts as we increase our liver focus and research and development in conjugated siRNAs. I look forward to working closely with him.”

Meanwhile, Silence Therapeutics has also appointed Dr Andy Richards as non-executive director and a member of the board with immediate effect.

Dr Richards currently chairs several UK biotechs, including Abcodia, Babraham Bioscience Technologies, Congenica and IXICO.

He previously held positions at AstraZeneca and PA Technology, and has contributed to the founding of Vectura, Arakis and Chiroscience Group.

Dr Stephen Parker, chairman of Silence Therapeutics, said: “We are delighted to have attracted Andy Richards, a recognised leader in the UK biotechnology sector, to join the board of Silence.

“We look forward to the benefit of his considerable experience in the commercial aspects of the sector as well as his overall guidance.”

8th September 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...